Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Core Scientific's Chief Legal Officer, Todd DuChene, reported transactions involving common stock, including a PSU grant settlement and share sales under a pre-arranged trading plan.

Summary

• Todd DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported several transactions related to the company's common stock.
• A performance-based restricted stock unit (PSU) grant was settled on March 31, 2026, resulting in the acquisition of 216,734 shares with no cost basis reported for this acquisition.
• Shares totaling 97,652 were withheld on March 31, 2026, to cover tax obligations upon the vesting of restricted stock units, at a price of $14.96 per share.
• Additionally, 10,000 shares were sold on April 1, 2026, under a Rule 10b5-1 trading plan adopted on December 5, 2025, at a weighted average price of $15.23.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves executive stock transactions, the use of a 10b5-1 plan and the settlement of performance-based RSUs are routine events and do not inherently signal positive or negative company performance.

Positives

• Settlement of performance-based restricted stock units indicates achievement of performance criteria and continued service by the executive.
• The use of a Rule 10b5-1 plan suggests a structured and pre-planned approach to stock transactions, potentially mitigating insider trading concerns.

Negatives

• The sale of 10,000 shares by a key executive could be interpreted as a reduction in direct ownership, although executed under a pre-defined plan.
• Withholding of shares for tax obligations, while standard, represents a reduction in the net shares received by the executive.

Risks

• The company's reliance on performance-based metrics for executive compensation could create pressure to meet short-term targets.
• The sale of shares, even under a 10b5-1 plan, might be perceived negatively by the market if not accompanied by strong positive company news.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by Core Scientific's Chief Legal Officer is a common practice to facilitate orderly stock sales while adhering to insider trading regulations, especially relevant in the volatile cryptocurrency mining sector where Core Scientific operates.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a 10b5-1 plan, may lead to short-term market perception shifts. The settlement of PSUs confirms performance targets were met, which could be viewed positively.

Next Steps

• The Reporting Person may provide further information regarding the specific prices of shares sold upon request from the SEC, security holders, or the Issuer.

Key Dates

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Options, Restricted Stock Units, 10b5-1 Plan, Executive Compensation, Securities Transaction